JP2014503516A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014503516A5 JP2014503516A5 JP2013543356A JP2013543356A JP2014503516A5 JP 2014503516 A5 JP2014503516 A5 JP 2014503516A5 JP 2013543356 A JP2013543356 A JP 2013543356A JP 2013543356 A JP2013543356 A JP 2013543356A JP 2014503516 A5 JP2014503516 A5 JP 2014503516A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- aryl
- nhc
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 39
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 22
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 21
- 125000002947 alkylene group Chemical group 0.000 claims description 20
- 125000000623 heterocyclic group Chemical group 0.000 claims description 19
- 125000003107 substituted aryl group Chemical group 0.000 claims description 18
- 239000003112 inhibitor Substances 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 14
- 125000004450 alkenylene group Chemical group 0.000 claims description 13
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 13
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 12
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 claims description 11
- 125000000304 alkynyl group Chemical group 0.000 claims description 11
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 125000006557 (C2-C5) alkylene group Chemical group 0.000 claims description 8
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 claims description 8
- 239000002777 nucleoside Substances 0.000 claims description 8
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 125000004419 alkynylene group Chemical group 0.000 claims description 5
- 125000000732 arylene group Chemical group 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 229940124771 HCV-NS3 protease inhibitor Drugs 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 claims description 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 4
- 229940124615 TLR 7 agonist Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 229940079322 interferon Drugs 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 4
- 229960000329 ribavirin Drugs 0.000 claims description 4
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000005549 heteroarylene group Chemical group 0.000 claims description 3
- -1 substituted Chemical class 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 241000711549 Hepacivirus C Species 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000005551 pyridylene group Chemical group 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 208000004576 Flaviviridae Infections Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 description 4
- 241000710781 Flaviviridae Species 0.000 description 2
- 125000005724 cycloalkenylene group Chemical group 0.000 description 2
- XAHPWAQGQWVKGX-MGBMXIFSSA-N CC(C)C(C(N[C@@H](Cc1cccc(O)c1)C(N(CCC1)N[C@@H]1C(OCc1cc(/C=C/CC[C@H]([C@H]2C)OC)c[s]1)=O)=O)=O)NC2=O Chemical compound CC(C)C(C(N[C@@H](Cc1cccc(O)c1)C(N(CCC1)N[C@@H]1C(OCc1cc(/C=C/CC[C@H]([C@H]2C)OC)c[s]1)=O)=O)=O)NC2=O XAHPWAQGQWVKGX-MGBMXIFSSA-N 0.000 description 1
- YTSTXQUADYXTMD-QJOREFBCSA-N CC(C)[C@@H](C(N[C@@H](Cc1cccc(O)c1)C(N(CCC1)NC1C(O[C@H](C)c1cc(/C=C/CC[C@H](C2)OC)ccc1)=O)=O)=O)NC2=O Chemical compound CC(C)[C@@H](C(N[C@@H](Cc1cccc(O)c1)C(N(CCC1)NC1C(O[C@H](C)c1cc(/C=C/CC[C@H](C2)OC)ccc1)=O)=O)=O)NC2=O YTSTXQUADYXTMD-QJOREFBCSA-N 0.000 description 1
- XIZJVYLKZRFALP-URIPJOPDSA-N CC(C)[C@@H](C(N[C@@H](Cc1cccc(O)c1)C(N(CCC1)N[C@@H]1C(NCc1cc(CC[C@@H]([C@H](C)C(C)[C@H]2C)OC)ccc1)=O)=O)=O)NC2=O Chemical compound CC(C)[C@@H](C(N[C@@H](Cc1cccc(O)c1)C(N(CCC1)N[C@@H]1C(NCc1cc(CC[C@@H]([C@H](C)C(C)[C@H]2C)OC)ccc1)=O)=O)=O)NC2=O XIZJVYLKZRFALP-URIPJOPDSA-N 0.000 description 1
- AUWZUEKUKUVCMS-RNGFSWOKSA-N CC(C)[C@@H](C(N[C@@H](Cc1cccc(O)c1)C(N(CCC1)N[C@@H]1C(OCCCC/C=C/CC[C@H]([C@H]1C)OC)=O)=O)=O)NC1=O Chemical compound CC(C)[C@@H](C(N[C@@H](Cc1cccc(O)c1)C(N(CCC1)N[C@@H]1C(OCCCC/C=C/CC[C@H]([C@H]1C)OC)=O)=O)=O)NC1=O AUWZUEKUKUVCMS-RNGFSWOKSA-N 0.000 description 1
- WPBKXFHONNKPJX-FKVNTWOLSA-N CCOC(CC/C=C/c1cccc(COC(C(CCC2)NN2C(C(Cc2cccc(O)c2)NC([C@H](C(C)C)N2)=O)=O)=O)c1)[C@@H](C)C2=O Chemical compound CCOC(CC/C=C/c1cccc(COC(C(CCC2)NN2C(C(Cc2cccc(O)c2)NC([C@H](C(C)C)N2)=O)=O)=O)c1)[C@@H](C)C2=O WPBKXFHONNKPJX-FKVNTWOLSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000005717 substituted cycloalkylene group Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000005556 thienylene group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42207110P | 2010-12-10 | 2010-12-10 | |
| US61/422,071 | 2010-12-10 | ||
| PCT/US2011/064009 WO2012078915A1 (en) | 2010-12-10 | 2011-12-08 | Macrocyclic inhibitors of flaviviridae viruses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014503516A JP2014503516A (ja) | 2014-02-13 |
| JP2014503516A5 true JP2014503516A5 (OSRAM) | 2015-01-29 |
| JP5847193B2 JP5847193B2 (ja) | 2016-01-20 |
Family
ID=45464097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013543356A Expired - Fee Related JP5847193B2 (ja) | 2010-12-10 | 2011-12-08 | フラビウイルス科ウイルスの大環状インヒビター |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8513184B2 (OSRAM) |
| EP (1) | EP2649076B1 (OSRAM) |
| JP (1) | JP5847193B2 (OSRAM) |
| KR (1) | KR20140031841A (OSRAM) |
| CN (1) | CN103403009B (OSRAM) |
| AR (1) | AR084217A1 (OSRAM) |
| AU (1) | AU2011338262B2 (OSRAM) |
| BR (1) | BR112013014063A2 (OSRAM) |
| CA (1) | CA2819824A1 (OSRAM) |
| EA (1) | EA026114B1 (OSRAM) |
| ES (1) | ES2536321T3 (OSRAM) |
| IL (1) | IL226739A (OSRAM) |
| MX (1) | MX2013006475A (OSRAM) |
| NZ (1) | NZ612159A (OSRAM) |
| PL (1) | PL2649076T3 (OSRAM) |
| PT (1) | PT2649076E (OSRAM) |
| SI (1) | SI2649076T1 (OSRAM) |
| TW (1) | TWI520966B (OSRAM) |
| UY (1) | UY33775A (OSRAM) |
| WO (1) | WO2012078915A1 (OSRAM) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2861604T (pt) | 2012-06-08 | 2017-05-05 | Gilead Sciences Inc | Inibidores macrocíclicos de vírus flaviridae |
| AR091279A1 (es) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| ES2656087T3 (es) * | 2012-06-08 | 2018-02-23 | Gilead Sciences, Inc. | Inhibidores macrocíclicos de virus Flaviviridae |
| AU2014370125B2 (en) * | 2013-12-23 | 2017-11-16 | Gilead Sciences, Inc. | Synthesis of a macrocyclic HCV NS3 inhibiting tripeptide |
| US9738646B2 (en) | 2014-09-16 | 2017-08-22 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
| SG11201705069YA (en) | 2014-12-26 | 2017-07-28 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| AU2016216673B2 (en) | 2015-03-04 | 2017-02-02 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| US20210292327A1 (en) | 2015-08-26 | 2021-09-23 | Gilead Sciences, Inc. | Deuterated toll-like receptor modulators |
| WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| EP3463469B1 (en) | 2016-05-27 | 2023-12-13 | Gilead Sciences, Inc. | Combination of ledipasvir and sofosbuvir for use in the treatment of hepatitis b virus infections in humans |
| BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| AU2017318601B2 (en) | 2016-09-02 | 2020-09-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| KR20230010826A (ko) | 2016-10-14 | 2023-01-19 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
| TW202510891A (zh) | 2017-01-31 | 2025-03-16 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
| JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| CN118440096A (zh) | 2017-06-20 | 2024-08-06 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| US11229638B2 (en) | 2017-08-22 | 2022-01-25 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| PL3706762T3 (pl) | 2017-12-07 | 2025-02-10 | Emory University | N4-hydroksycytydyna i pochodne oraz związane z nimi zastosowania przeciwwirusowe |
| US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| JP7062792B2 (ja) | 2018-02-13 | 2022-05-06 | ギリアード サイエンシーズ， インコーポレイテッド | Ｐｄ－１／ｐｄ－ｌ１阻害剤 |
| CA3091142C (en) | 2018-02-26 | 2023-04-11 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| EP3781556B1 (en) | 2018-04-19 | 2025-06-18 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| KR102629921B1 (ko) | 2018-07-06 | 2024-01-31 | 길리애드 사이언시즈, 인코포레이티드 | 치료 헤테로시클릭 화합물 |
| CA3103987C (en) | 2018-07-06 | 2023-08-01 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| CN118221646A (zh) | 2018-07-13 | 2024-06-21 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| KR102635333B1 (ko) | 2018-10-24 | 2024-02-15 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| MX2021005047A (es) | 2018-10-31 | 2021-09-08 | Gilead Sciences Inc | Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1. |
| CN117105933A (zh) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
| AU2020231115B2 (en) | 2019-03-07 | 2025-02-20 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| DK3934757T3 (da) | 2019-03-07 | 2023-04-17 | Inst Of Organic Chemistry And Biochemistry Ascr V V I | 2'3'-cykliske dinukleotider og prodrugs deraf |
| US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| CA3140708A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
| PE20220231A1 (es) | 2019-06-25 | 2022-02-07 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso |
| WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| EP4458975A3 (en) | 2019-09-30 | 2025-02-12 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
| AU2020379731A1 (en) | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
| CA3159561A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| EP4069729B1 (en) | 2019-12-06 | 2025-01-22 | Precision BioSciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| AR121620A1 (es) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos |
| US12110305B2 (en) | 2020-08-07 | 2024-10-08 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
| PE20231207A1 (es) | 2020-09-15 | 2023-08-17 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| EP4074317A1 (en) | 2021-04-14 | 2022-10-19 | Bayer AG | Phosphorus derivatives as novel sos1 inhibitors |
| PE20240089A1 (es) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cancer |
| AU2022274607A1 (en) | 2021-05-13 | 2023-11-16 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| JP7686086B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物 |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN114796193B (zh) * | 2022-05-13 | 2023-07-18 | 黑龙江八一农垦大学 | 抗牛病毒性腹泻病毒的中药单体 |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR006514A1 (es) | 1995-07-04 | 1999-09-08 | Sandoz Ag | Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende |
| US6124453A (en) | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
| WO2006138507A1 (en) * | 2005-06-17 | 2006-12-28 | Novartis Ag | Use of sanglifehrin in hcv |
-
2011
- 2011-12-07 AR ARP110104596A patent/AR084217A1/es unknown
- 2011-12-07 UY UY0001033775A patent/UY33775A/es not_active Application Discontinuation
- 2011-12-08 EA EA201390822A patent/EA026114B1/ru not_active IP Right Cessation
- 2011-12-08 WO PCT/US2011/064009 patent/WO2012078915A1/en not_active Ceased
- 2011-12-08 PT PT118056977T patent/PT2649076E/pt unknown
- 2011-12-08 BR BR112013014063A patent/BR112013014063A2/pt not_active IP Right Cessation
- 2011-12-08 JP JP2013543356A patent/JP5847193B2/ja not_active Expired - Fee Related
- 2011-12-08 AU AU2011338262A patent/AU2011338262B2/en not_active Ceased
- 2011-12-08 NZ NZ612159A patent/NZ612159A/en not_active IP Right Cessation
- 2011-12-08 ES ES11805697.7T patent/ES2536321T3/es active Active
- 2011-12-08 KR KR1020137017607A patent/KR20140031841A/ko not_active Abandoned
- 2011-12-08 CA CA2819824A patent/CA2819824A1/en not_active Abandoned
- 2011-12-08 US US13/315,069 patent/US8513184B2/en not_active Expired - Fee Related
- 2011-12-08 EP EP11805697.7A patent/EP2649076B1/en active Active
- 2011-12-08 SI SI201130434T patent/SI2649076T1/sl unknown
- 2011-12-08 PL PL11805697T patent/PL2649076T3/pl unknown
- 2011-12-08 CN CN201180066396.4A patent/CN103403009B/zh not_active Expired - Fee Related
- 2011-12-08 MX MX2013006475A patent/MX2013006475A/es active IP Right Grant
- 2011-12-09 TW TW100145540A patent/TWI520966B/zh not_active IP Right Cessation
-
2013
- 2013-06-04 IL IL226739A patent/IL226739A/en active IP Right Grant
- 2013-07-15 US US13/942,501 patent/US8933015B2/en not_active Expired - Fee Related